Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research

University of Toronto

$250,000.00

Developing a Novel Modular Nanoparticle Vaccine Strategy to Induce Durable Systemic and Mucosal HIV Envelope Specific Antibodies

FY 2016-17

Summary
36.7 million people live with HIV infection, the virus that causes AIDS, which has produced considerable global morbidity and mortality. An effective vaccine is not yet available and treatment is lifelong. Recent advances in the HIV vaccine field have produced a number of candidate vaccines that could be considered for testing in the near future, although they may not be fully optimized yet. Current vaccines have a number of problems preventing their use. One problem is an inability for the vaccines to stimulate the body to make antibodies against the virus that last a long time in the body (many years). Current vaccines if used would require multiple vaccinations, possibly yearly. A 2nd problem is the vaccines needs to make antibodies at the mucous membranes where the virus is transmitted, and this has not yet been optimally achieved. A 3rd problem is that vaccines can activate the immune system and make one more susceptible to getting infected while the vaccine is taking effect. This proposal will draw upon recent advances in bio-engineering and nano-biology to create vaccines made up of particles that can stimulate the body to make strong antibodies, that last long, are found in the mucous membranes and do not over-stimulate the immune system. In order to achieve this, careful step-by-step approaches in experimentation are needed. In this 2 year grant, we will delineate the early phase of such a graduated approach in order to achieve a safe and effective vaccine.
Program
Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
365746
Name
Ostrowski Mario A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Innovative Biomedical and Clinical HIV/AIDS Research
Projecttitle
Developing a Novel Modular Nanoparticle Vaccine Strategy to Induce Durable Systemic and Mucosal HIV Envelope Specific Antibodies
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$250,000
Cihrequipment2
$0
Programname2
Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research
Keyworddelim
Antibodies; B Cells; Hiv Vaccines; Nanoparticles
Abstract
36.7 million people live with HIV infection, the virus that causes AIDS, which has produced considerable global morbidity and mortality. An effective vaccine is not yet available and treatment is lifelong. Recent advances in the HIV vaccine field have produced a number of candidate vaccines that could be considered for testing in the near future, although they may not be fully optimized yet. Current vaccines have a number of problems preventing their use. One problem is an inability for the vaccines to stimulate the body to make antibodies against the virus that last a long time in the body (many years). Current vaccines if used would require multiple vaccinations, possibly yearly. A 2nd problem is the vaccines needs to make antibodies at the mucous membranes where the virus is transmitted, and this has not yet been optimally achieved. A 3rd problem is that vaccines can activate the immune system and make one more susceptible to getting infected while the vaccine is taking effect. This proposal will draw upon recent advances in bio-engineering and nano-biology to create vaccines made up of particles that can stimulate the body to make strong antibodies, that last long, are found in the mucous membranes and do not over-stimulate the immune system. In order to achieve this, careful step-by-step approaches in experimentation are needed. In this 2 year grant, we will delineate the early phase of such a graduated approach in order to achieve a safe and effective vaccine.
Competitiondate
201702
Approvedterm2
1 yr 6 mths
Pinamesdelim
Ostrowski, Mario A; Reinhard, Robert J
Approvedterm
1 an 6 mois
Cihrcontribution2
~ $250,000~ $0~